Newsroom

Press Releases

20Juin2016
Fast-growing biopharmaceutical company NOVADIP develops its product portfolio and moves to new premises offering on-site R&D and GMP facilities

Mont-Saint-Guibert, Belgium – June 21, 2016 – NOVADIP BIOSCIENCES, a biopharmaceutical spin-off company of Université catholique de Louvain, announces the

Read More
09Sep2015
Novadip closes EUR 28 million Series A Round with US and Belgian investors to advance breakthrough cell therapy pipeline

EN – FR – NL Louvain-la-Neuve, Belgium – September 10, 2015 – Novadip Biosciences, a biopharmaceutical spin-off company of Université catholique de L

Read More
14Déc2014
Gil beyen joins novadip biosciences board of directors

Louvain-la-Neuve, Belgium – December 15, 2014 – NOVADIP BIOSCIENCES, an innovative biopharmaceutical company specializing in the discovery and development of new

Read More

Press Articles

10Juin2016
L’Echo : Les Belges présents en force à la plus grande bourse biotech du globe

Lien vers l’article : Les Belges présents en force à la plus grande bourse biotech du globe

Read More
28Mai2015
La Libre : La biopharmacie belge en mal de capital risque.

Novadip, parcours du combattant

Read More
09Mai2015
L’Echo : Atelier plasticine

Pour reconstruire le tissu osseux, Novadip Biosciences a mis au point un genre de plasticine faite à partir des cellules souches du patient. Ultra...

Read More

Publications

16Mar2013
Critical size bone defect reconstruction by an autologous 3D osteogenic-like tissue derived from differentiated adipose MSCs

For critical size bone defects and bone non-unions, bone tissue engineering using osteoblastic differentiated adipose mesenchymal stem cells (AMSCs) is limited by the nee

Read More
27Août2011
The enhanced performance of bone allografts using osteogenic-differentiated adipose-derived mesenchymal stem cells

Adipose tissue was only recently considered as a potential source of mesenchymal stem cells (MSCs) for bone tissue engineering. To improve the osteogenicity of...

Read More